Christopher Ianelli, MD, PhD, Founder and CEO, iSpecimen, founded iSpecimen in response to the precision medicine movement and the growing demand for biospecimens by life science researchers. Under his leadership, iSpecimen has become a dominant player in research sample procurement, recently developing and launching the industry’s first marketplace platform connecting researchers with healthcare providers and biorepositories.
Prior to launching iSpecimen, Chris served as Managing Director at Leerink Partners (formerly Leerink Swann), a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets. At Leerink, he launched Health Insight Technologies, a healthcare informatics company that was spun out of the firm as Humedica and acquired by UnitedHealth Group in 2013.
Prior to Leerink, Chris was a co-founder and Managing Director of Boston Medical & Scientific Advisors, a healthcare investment research firm ultimately acquired by Leerink. He received both his PhD in Immunology and his MD from Tufts University and completed his residency training, including a year as Chief Resident, in Pathology at Brigham & Women’s Hospital and Harvard Medical School.